Compare RYTM & MRCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYTM | MRCY |
|---|---|---|
| Founded | 2008 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.1B |
| IPO Year | 2017 | 1997 |
| Metric | RYTM | MRCY |
|---|---|---|
| Price | $82.62 | $79.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $131.14 | $80.00 |
| AVG Volume (30 Days) | ★ 505.0K | 402.6K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.34 | ★ 72.69 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $912,020,000.00 |
| Revenue This Year | $55.34 | $6.59 |
| Revenue Next Year | $86.06 | $9.56 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9.19 |
| 52 Week Low | $55.31 | $44.01 |
| 52 Week High | $122.20 | $103.81 |
| Indicator | RYTM | MRCY |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 48.34 |
| Support Level | $74.50 | $71.79 |
| Resistance Level | $90.79 | $79.27 |
| Average True Range (ATR) | 3.24 | 3.38 |
| MACD | -0.28 | -0.33 |
| Stochastic Oscillator | 23.60 | 38.36 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.